Edition:
India

People: Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

74.54USD
11:16pm IST
Change (% chg)

$0.33 (+0.44%)
Prev Close
$74.21
Open
$74.47
Day's High
$74.59
Day's Low
$72.76
Volume
122,094
Avg. Vol
437,860
52-wk High
$106.69
52-wk Low
$70.90

Grey, Michael 

Mr. Michael G. Grey serves as an Independent Director of Biomarin Pharmaceutical Inc. He joined our Board in December 2005 and serves as the Chair of the Compensation Committee. Mr. Grey currently serves as Executive Chairman of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company (Amplyx), a position he has held since December 2016, and previously served as President and Chief Executive Officer of Amplyx from October 2015 to December 2016. Mr. Grey also currently serves as Executive Chairman of Reneo Pharmaceuticals, Inc., a biopharmaceutical company, a position he has held since January 2018, and previously served as Chief Executive Officer from October 2014 to December 2017. He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a private biotechnology company, from February 2011 until it was acquired by Shire plc in May 2014. He has also served as a Venture Partner with Pappas Ventures, a life sciences venture capital firm, since January 2010. Between January and September 2009, he served as President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. From 1974 to 1993, he served in various roles with Glaxo, Inc. and Glaxo Holdings, plc.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 183,680
Long-Term Incentive Plans, USD --
All Other, USD 273,715
Fiscal Year Total, USD 457,395

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jean-Jacques Bienaime

15,917,000

Daniel Spiegelman

4,641,880

Henry Fuchs

7,045,420

G. Eric Davis

2,708,210

Jeff Ajer

4,568,300

Robert Baffi

4,473,230
As Of  31 Dec 2017